Neogen Corp 8-K, filed Jan 7, 2021
Neogen Corp (NEOG)
About this 8-K
Neogen Corp filed this 8-K on January 7, 2021, reporting on events of January 4, 2021.
Items reported
- Item 2.01: Completed an acquisition or sale of assets
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.01 | Completion of Acquisition of Disposition of Assets |
On January 4, 2021, Neogen Corporation announced that it had acquired Ireland-based Megazyme, Ltd. — a supplier of analytical solutions used by quality control laboratories in the global food and beverage industries. Megazyme, founded in 1988, develops and refines analytical methods used to measure the carbohydrates and enzymes in grain, cereal, wine, dairy and other food products, that affect quality. Megazyme will continue to operate as a standalone business in Bray, Ireland, and will be managed through Neogen’s European operations in Scotland.
A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | ||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEOGEN CORPORATION | ||||||
| (Registrant) | ||||||
| Date: January 6, 2021 | ||||||
| /s/ Steven J. Quinlan | ||||||
| Steven J. Quinlan | ||||||
| Vice President & CFO | ||||||
Exhibit 99.1
FOR IMMEDIATE RELEASE
| CONTACT: | Steven J. Quinlan, Vice President & CFO |
| 517/372-9200 |
Neogen acquires food quality diagnostics company
LANSING, Mich., Jan. 4, 2021 — Neogen Corporation (NASDAQ: NEOG) announced today that it has acquired Ireland-based Megazyme, Ltd. — a major supplier of analytical solutions used by quality control laboratories in the global food and beverage industries. Megazyme will continue to operate as a standalone business, and will be managed through Neogen’s European operations in Scotland.
Megazyme was founded in 1988 with the core mission of developing and refining analytical methods used to measure the carbohydrates and enzymes in grain and cereal products that affect quality. Subsequently, their interests expanded to the wine, dairy and food industries. Megazyme’s diagnostics, which are exclusively developed and manufactured in-house, have since attracted worldwide acclaim for their genuinely innovative methodologies and exceptional component purity.
“Neogen has had a long relationship with Megazyme and highly respects the business and products Dr. McCleary has developed and built,” said Dr. Jason Lilly, Neogen’s vice president of international business. “The addition of Megazyme to the global Neogen business will strengthen our relationships with the largest food producers and those companies that are aligned with our mission of food security and quality. The integration of the Megazyme product line into Neogen’s traditional food safety products will allow us to expand our commercial relationships across food companies and ensure not only safe food, but the highest quality and nutritional content.”
“After more than 30 years of building Megazyme to a leading food diagnostics company, I’m very pleased to see the company becoming a part of Neogen’s comprehensive solution for food security and quality,” said Dr. Barry McCleary, Megazyme’s co-founder and CEO, who will continue to be a strategic advisor to Neogen in the area of food quality diagnostics. “I am honored to be part of such a great company and look forward to working with Neogen to develop and market new and innovative dietary fiber and carbohydrate analysis products and solutions.”
Megazyme was founded in 1988 in Sydney, Australia, and has been based in Bray, Ireland, since 1996. Since its beginning, Megazyme has focused on the development of test kits and reagents for use in analytical and research laboratories.
“Neogen’s acquisition of Megazyme provides a natural and complementary expansion of our food diagnostics portfolio while aligning with a mission of providing comprehensive leading solutions to global food producers,” said Doug Hopek, Neogen’s senior director and head of corporate development. “Megazyme is a rapid diagnostics business that extends our traditional food safety products and services.”
As a company, Megazyme is recognized as one of Europe’s most dynamic and innovative life sciences businesses. Megazyme won the 2016 Irish Times Innovation Award in the Life Sciences and Healthcare category, represented Ireland in the European Business Awards in 2017 and 2018 and was named “Food Laboratory of the Year” in the Irish Laboratory Awards, 2020. For more information on the company, visit www.megazyme.com.
Terms of the agreement were not disclosed.
Neogen Corporation develops and markets products dedicated to food and animal safety. The company’s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen’s Animal Safety Division is a leader in the development of animal genomics along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.
###